Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics (BTAI)
:BTAI
BTAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.72 - $49.58
Previous CloseN/A
Volume1.10M
Average Volume (3M)9.24M
Market Cap
$7.67M
Enterprise Value$90.44M
Total Cash (Recent Filing)$42.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 12, 2025EPS Estimate
-6.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-34.43
Shares Outstanding3,290,192
10 Day Avg. Volume909,527
30 Day Avg. Volume9,237,172
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap11.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit753.67
Enterprise Value/Ebitda-1.61
Forecast
1Y Price Target
$49.25Price Target Upside2013.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Phase 3 SERENITY At-Home study for Igalmi is seen as a positive development, potentially driving increased revenue.
Financial ResilienceBioxcel Therapeutics has successfully renegotiated its credit agreement, which helps address the company's cash concerns.
Regulatory ApprovalBTAI shares are trading +150% after announcing that the FDA has concluded the site inspection for one of the sites in the TRANQUILITY II phase 3 trial, with voluntary action indicated.
Bears Say
Financial PerformanceSales reported were roughly $214K, well below the $1.2M that was previously forecasted.
Financial RisksThe company's financial situation is a major concern due to limited cash and the need to raise additional funds to meet debt covenants.
Stock DilutionThe proposed follow-on offering is necessary but will be highly dilutive due to the current depressed stock price.
---
Ownership Overview
46.42% Insiders
4.16% Mutual Funds
0.10% Other Institutional Investors
46.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BTAI FAQ
What was Bioxcel Therapeutics’s price range in the past 12 months?
Bioxcel Therapeutics lowest stock price was $1.72 and its highest was $49.58 in the past 12 months.
What is Bioxcel Therapeutics’s market cap?
Bioxcel Therapeutics’s market cap is $7.67M.
When is Bioxcel Therapeutics’s upcoming earnings report date?
Bioxcel Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 49 days.
How were Bioxcel Therapeutics’s earnings last quarter?
Currently, no data Available
Is Bioxcel Therapeutics overvalued?
According to Wall Street analysts Bioxcel Therapeutics’s price is currently Undervalued.
Does Bioxcel Therapeutics pay dividends?
Bioxcel Therapeutics does not currently pay dividends.
What is Bioxcel Therapeutics’s EPS estimate?
Bioxcel Therapeutics’s EPS estimate is -6.38.
How many shares outstanding does Bioxcel Therapeutics have?
Bioxcel Therapeutics has 3,290,192 shares outstanding.
What happened to Bioxcel Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioxcel Therapeutics?
Among the largest hedge funds holding Bioxcel Therapeutics’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics’s shares valued at 0.
---
Bioxcel Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.25 (2013.73% Upside)
$49.25 (2013.73% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.85%
12-Months-Change
Fundamentals
Return on Equity
82.91%
Trailing 12-Months
Asset Growth
-51.33%
Trailing 12-Months
Company Description
Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
BTAI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted progress in clinical trials and significant financial improvements, such as reduced net loss and increased revenue over the nine-month period. However, challenges remain with decreased quarterly revenue, increased costs, and uncertainties regarding cash runway and financing.Read More>---
BTAI Stock 12 Month Forecast
Average Price Target
$49.25
▲(2013.73% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Corcept Therapeutics
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering BTAI
1 Year
1 Year Success Rate
12/40 ratings generated profit
1 Year Average Return
+33.30%
reiterated a buy rating 3 months ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 30.00% of your transactions generating a profit, with an average return of +33.30% per trade.
---